IDEAYA Biosciences, Inc. (IDYA) Stock Forecast
IDYA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 15 analysts
- Price target
- $52.29 average of analyst targets
- Upside to target
- +59.2% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-1.26
- 52-week range
- $27.60 – $42.48
IDYA analyst ratings
15 analystsNumber of analysts at each rating.
IDYA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IDYA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.16 | −$1.42 | −$0.84 | $1.33 | −187.5% | 14 |
| Current fiscal year (2026) | −$4.58 | −$5.20 | −$4.02 | −$1.28 | −258.1% | 14 |
| Next fiscal year (2027) | −$4.16 | −$5.43 | −$1.78 | −$4.58 | +9.2% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IDYA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.1M | $0 | $35.0M | −96.6% | 15 |
| Current fiscal year (2026) | $40.2M | $15.4M | $85.5M | −81.6% | 16 |
| Next fiscal year (2027) | $116.4M | $17.7M | $244.6M | +189.9% | 15 |
IDYA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IDYA revenue: reported and forecast
IDYA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.05 | −$1.17 | −$1.17 | −$1.16 | −$1.16 | +10.9% | 1 up · 11 down |
| Current fiscal year (2026) | −$4.28 | −$4.61 | −$4.61 | −$4.58 | −$4.58 | +7.0% | 1 up · 12 down |
| Next fiscal year (2027) | −$3.65 | −$4.11 | −$4.10 | −$4.01 | −$4.16 | +14.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IDYA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IDYA beat in 4 of 12.
What analysts expect from IDYA
15 analysts cover IDEAYA Biosciences; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.29, 59.2% above the latest close of $32.85. Analysts expect earnings of −$4.58 per share for 2026, −258.1% from a year earlier. For 2027 the average estimate is −$4.16 per share on revenue of $116.4 million. IDEAYA Biosciences beat the EPS estimate in 4 of the last 12 quarters.
Related: IDYA income statement, IDYA key metrics, IDYA chart. See the IDYA stock overview for the latest quote and news.
IDYA forecast FAQ
What is IDEAYA Biosciences's price target?
The average analyst price target for IDEAYA Biosciences is $52.29, 59.2% above the latest close of $32.85.
Is IDEAYA Biosciences a buy, hold or sell?
Of 15 analysts covering IDEAYA Biosciences, 11 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is IDEAYA Biosciences's EPS forecast?
Analysts forecast −$4.58 per share for 2026 (range −$5.20 to −$4.02); for 2027 the estimate is −$4.16.
What is IDEAYA Biosciences's revenue forecast?
The average revenue estimate for 2026 is $40.2 million, growth of −81.6%; for 2027 it is $116.4 million.
When does IDEAYA Biosciences report earnings?
IDEAYA Biosciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-1.26.
Does IDEAYA Biosciences usually beat earnings estimates?
IDEAYA Biosciences reported EPS at or above the analyst estimate in 4 of the last 12 quarters.